

North America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)

Market Report | 2023-01-18 | 146 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The North America overactive bladder treatment market is expected to grow from US\$ 1,682.29 million in 2022 to US\$ 2,059.43 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Increase in Prevalence of Urinary Incontinence Drives North America Overactive Bladder Treatment Market

Urinary incontinence is the loss of bladder control caused due to the improper functioning of the muscles and nerves that control the passage of urine through the bladder. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. As per the Office on Women's Health, a division of the US Department of Health and Human Services, the prevalence of incontinence in women is twice as in men, and aging, pregnancy, childbirth, and menopause can be the key factors leading to this condition in women. A few other factors affecting the function of muscles and nerves include overweight, constipation, or pelvic surgeries. As stated by the North American Menopause Society (NAMS), in the US, the prevalence of urinary incontinence was 17.1% among women aged 20 years or more and 38% in women aged 60 years and older in 2021. Urinary incontinence can affect women at any age; however, it is more common in older women due to hormonal changes during menopause. Thus, the surge in urinary related diseases is directly driving the North America overactive bladder treatment market .

North America Overactive Bladder Treatment Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the overactive bladder treatment market in 2021, owing to the increase in the geriatric population and prevalence of overactive diseases and Parkinson's Disease. According to Parkinson's Foundation, ~1 million people in the US are suffering from Parkinson's Disease, and it is likely to reach 1.2 million by 2030. Although overactive bladder can occur at any age, it is quite prevalent in the population aged above 60 years. As per the Administration for Community Living, 16% of the US population was aged 65 and above in 2019, and it is expected to reach ~21.6% by 2040. The Population Reference Bureau (PRB) stated that the number of Americans aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. According to Cleveland Clinic Organization, ~33 million adults in the US are affected by an overactive bladder. Further, an article by John Wiley & Sons, Inc. stated that ~17% of the US population suffers from this condition. Thus, the demand for overactive bladder treatment is increasing across the region.

North America Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US\$ Million)

North America Overactive Bladder Treatment Market Segmentation

The North America overactive bladder treatment market is segmented based on pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the North America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.

Based on disease type, the North America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Axonics Modulation Technologies, Inc; Colorado Urology Associates, PLLC; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic PLC; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the North America overactive bladder treatment market.

Table of Contents:

TABLE OF CONTENTS

1. Introduction
 - 1.1 Study Scope
 - 1.2 The Insight Partners Research Report Guidance
 - 1.3 Market Segmentation
 - 1.3.1 North America Overactive Bladder Treatment Market- By Pharmacotherapy
 - 1.3.2 North America Overactive Bladder Treatment Market- By Disease Type
 - 1.3.3 North America Overactive Bladder Treatment Market - By Country
2. North America Overactive Bladder Treatment Market Key Takeaways
3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
4. North America Overactive Bladder Treatment Market Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.1 Overview
- 4.2 North America PEST Analysis
- 4.3 Expert Opinion
- 5. North America Overactive Bladder Treatment Market Key Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 Increase in Prevalence of Urinary Incontinence
 - 5.1.2 Growing Incidence of Urinary Tract Infections
 - 5.2 Key Market Restraints
 - 5.2.1 Recalls of Therapeutic Drugs
 - 5.3 Key Market Opportunities
 - 5.3.1 Increasing Number of Mergers and Acquisitions
 - 5.4 Future Trends
 - 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
 - 5.5 Impact analysis
- 6. North America Overactive Bladder Treatment Market - North America Analysis
 - 6.1 North America Overactive Bladder Treatment Market Revenue Forecast and Analysis
- 7. North America Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy
 - 7.1 Overview
 - 7.2 North America Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
 - 7.3 Mirabegron
 - 7.3.1 Overview
 - 7.3.2 Mirabegron: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
 - 7.4 Botox
 - 7.4.1 Overview
 - 7.4.2 Botox: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
 - 7.5 Neurostimulation
 - 7.5.1 Overview
 - 7.5.2 Neurostimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.5.3 Transcutaneous Sacral Nerve Stimulation
 - 7.5.3.1 Overview
 - 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.5.4 Transcutaneous Tibial Nerve Stimulation
 - 7.5.4.1 Overview
 - 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
 - 7.5.5.1 Overview
 - 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.5.6 Others
 - 7.5.6.1 Overview
 - 7.5.6.2 Others: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.6 Anticholinergics
 - 7.6.1 Overview
 - 7.6.2 Anticholinergics: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
 - 7.6.3 Solifenacin

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.6.3.1 Overview
- 7.6.3.2 Solifenacin: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.4 Oxybutynin
 - 7.6.4.1 Overview
 - 7.6.4.2 Oxybutynin: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.5 Fesoterodine
 - 7.6.5.1 Overview
 - 7.6.5.2 Fesoterodine: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.6 Darifenacin
 - 7.6.6.1 Overview
 - 7.6.6.2 Darifenacin: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.7 Tolterodine
 - 7.6.7.1 Overview
 - 7.6.7.2 Tolterodine: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.8 Trosipium
 - 7.6.8.1 Overview
 - 7.6.8.2 Trosipium: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.6.9 Other Anticholinergics
 - 7.6.9.1 Overview
 - 7.6.9.2 Other Anticholinergics: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Million)
- 7.7 Intravesical Instillation
 - 7.7.1 Overview
 - 7.7.2 Intravesical Instillation: North America Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
- 8. North America Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type
 - 8.1 Overview
 - 8.2 North America Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
 - 8.3 Idiopathic Overactive Bladder
 - 8.3.1 Overview
 - 8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
 - 8.4 Neurogenic Overactive Bladder
 - 8.4.1 Overview
 - 8.4.2 Neurogenic: Overactive Bladder Market Revenue and Forecast to 2028 (US\$ Mn)
- 9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis
 - 9.1 Overview
 - 9.1.2 North America: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
 - 9.1.2.1 US: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.1.1 US: Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.1.2 US: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.1.2.1 US: Overactive Bladder Treatment Market, by Anticholinergics- Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.1.2.2 US: Overactive Bladder Treatment Market, by Neurostimulation- Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.1.3 US: Overactive Bladder Treatment Market, by Disease Type- Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.2 Canada: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.2.1 Canada: Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.2.2 Canada: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.2.2.1 Canada: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.2.2.2 Canada: Overactive Bladder Treatment Market, by Neurostimulation- Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.2.3 Canada: Overactive Bladder Treatment Market, by Disease Type- Revenue and Forecast to 2028 (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.2.3 Mexico: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.3.1 Mexico: Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.3.2 Mexico: Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.3.2.1 Mexico: Overactive Bladder Treatment Market, by Anticholinergics - Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.3.2.2 Mexico: Overactive Bladder Treatment Market, by Neurostimulation- Revenue and Forecast to 2028 (US\$ Million)
 - 9.1.2.3.3 Mexico: Overactive Bladder Treatment Market, by Disease Type- Revenue and Forecast to 2028 (US\$ Million)
- 10. Overactive Bladder Treatment Market- Industry Landscape
 - 10.1 Overview
 - 10.2 Organic Developments
 - 10.2.1 Overview
- 11. Company Profiles
 - 11.1 Alembic Pharmaceuticals Limited
 - 11.1.1 Key Facts
 - 11.1.2 Business Description
 - 11.1.3 Products and Services
 - 11.1.4 Financial Overview
 - 11.1.5 SWOT Analysis
 - 11.1.6 Key Developments
 - 11.2 Astellas Pharma Inc
 - 11.2.1 Key Facts
 - 11.2.2 Business Description
 - 11.2.3 Products and Services
 - 11.2.4 Financial Overview
 - 11.2.5 SWOT Analysis
 - 11.2.6 Key Developments
 - 11.3 AbbVie Inc
 - 11.3.1 Key Facts
 - 11.3.2 Business Description
 - 11.3.3 Products and Services
 - 11.3.4 Financial Overview
 - 11.3.5 SWOT Analysis
 - 11.3.6 Key Developments
 - 11.4 Teva Pharmaceutical Industries Ltd
 - 11.4.1 Key Facts
 - 11.4.2 Business Description
 - 11.4.3 Products and Services
 - 11.4.4 Financial Overview
 - 11.4.5 SWOT Analysis
 - 11.4.6 Key Developments
 - 11.5 Endo Pharmaceuticals Inc.
 - 11.5.1 Key Facts
 - 11.5.2 Business Description
 - 11.5.3 Products and Services
 - 11.5.4 Financial Overview
 - 11.5.5 SWOT Analysis
 - 11.5.6 Key Developments
 - 11.6 Hisamitsu Pharmaceutical Co. Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 Medtronic Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
- 11.8 Colorado Urology Associates, PLLC
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
- 11.9 Axonics Modulation Technologies, Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
- 11.10 Pfizer Inc
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
- 12. Appendix
- 12.1 About The Insight Partners
- 12.2 Glossary of Terms

North America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)

Market Report | 2023-01-18 | 146 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-03

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com